NASDAQ: BEAM
Beam Therapeutics Inc.
Healthcare · Biotechnology
After hours: $26.92(+0.64%) · as of 7:59 PM ET
Market Cap
$2.75B
52w High
$38.26
52w Low
$15.60
P/E
-32.62
Volume
1.22M
Outstanding Shares
102.88M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 51.73% over the last year. Revenue grew 158.88% over the trailing twelve months. Operating margin moved from -739.94% to -242.27%. Free cash flow declined 4.84% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 26th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -242.27%. Revenue grew 158.88% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 4.84%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
18
Buy
8
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 3, 2026
Q4 FY26 · EPS est -$1.16 · Revenue est $8.72M
View